Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis

Table 1 the primary characteristics of the eligible studies in more detail

Studies (year)	Study type	Surgery	Treatment regimen (Dosage of TXA)		Treatment regimen (number)		Treatment regimen (Age)
Studies (year)	Study type	Surgery	oral	intravenous	oral	intravenous	oral	intravenous
Kayupovt, 2017	RCT	THA	1950 mg/kg	1000 mg	40	43	60	55
Yuan, 2017	RCT	TKA	40 mg/kg	20 mg/kg	140	140	63.2	63.7
Fillingham, 2016	RCT	TKA	1950 mg	1000 mg	34	37	62	63
Irwin, 2013	RCS	TKA and THA	25 mg/kg (maximum 2 g)	15 mg/kg (maximum 1.2 g)	302	2698	67.6	68.2
Zohar, 2004	RCT	TKA	4000 mg	10 mg/kg for 12 h	20	20	69	73
Cao, 2018	RCT	THA	2000 mg	20 mg/kg	54	54	55.7	55.7
Gortemoller, 2017	RCS	TKA and THA	1950 mg	1000 mg	165	165	67	68
Luo, 2017	RCS	THA	2000 mg	20 mg/kg	60	60	67.6	66.98
Wang, 2018	RCT	TKA	2000 mg	20 mg/kg	60	60	63.91	66.9

TXA tranexamic acid, THA total hip arthroplasty, TKA total knee arthroplasty, RCT randomized controlled trial, RCS retrospective cohort study

ISSN: 1471-2474